Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1983 Jul;24(1):95–103. doi: 10.1128/aac.24.1.95

Therapeutic activities of 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine and -thymine alone and in combination with acyclovir and vidarabine in mice infected intracerebrally with herpes simplex virus.

R F Schinazi, J Peters, M K Sokol, A J Nahmias
PMCID: PMC185110  PMID: 6625559

Abstract

The therapeutic effectiveness of two new antiviral agents, 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine and 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)thymine, was compared with that of acyclovir and vidarabine. In mice inoculated intracerebrally with high 50% lethal doses of herpes simplex virus type 2, nontoxic intraperitoneal or oral treatments with the two new fluorinated antiviral agents were highly effective in reducing mortality. The two drugs were also effective when treatment was begun as late as 48 h after virus inoculation. The relative order of potencies of the drugs when compared on a molar basis or in terms of therapeutic index was 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)thymine much greater than 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5-iodocytosine greater than vidarabine approximately to acyclovir. The new pyrimidine analogs were also found to lack immunosuppressive activity in mice. The combination of 1-(2-fluoro-2-deoxy-beta-=D-arabinofuranosyl)-5-iodocytosine and vidarabine was the most effective; significantly greater reduction in mortality was achieved with this combination than with either drug alone. Thirty minutes after intraperitoneal treatment with the fluorinated analogs, the drugs (or their metabolites) were transported to the brains of virus-inoculated and normal mice at levels about one-third to two thirds those in the blood. The levels of 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)thymine in the blood or brain were consistently higher than those found with equivalent intraperitoneal doses of the 5-iodocytosine analog.

Full text

PDF
95

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Biron K. K., Noblin J. E., de Miranda P., Elion G. B. Uptake, distribution, and anabolism of acyclovir in herpes simplex virus-infected mice. Antimicrob Agents Chemother. 1982 Jan;21(1):44–50. doi: 10.1128/aac.21.1.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Darville J. M., Blyth W. A. Neutralising antibody in mice with primary and recurrent herpes simplex virus infection. Arch Virol. 1982;71(4):303–310. doi: 10.1007/BF01315060. [DOI] [PubMed] [Google Scholar]
  3. De Clercq E., Descamps J., Verhelst G., Walker R. T., Jones A. S., Torrence P. F., Shugar D. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis. 1980 May;141(5):563–574. doi: 10.1093/infdis/141.5.563. [DOI] [PubMed] [Google Scholar]
  4. Ejercito P. M., Kieff E. D., Roizman B. Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol. 1968 May;2(3):357–364. doi: 10.1099/0022-1317-2-3-357. [DOI] [PubMed] [Google Scholar]
  5. Kern E. R., Overall J. C., Jr, Glasgow L. A. Herpesvirus hominis infection in newborn mice. I. An experimental model and therapy with iododeoxyuridine. J Infect Dis. 1973 Sep;128(3):290–299. doi: 10.1093/infdis/128.3.290. [DOI] [PubMed] [Google Scholar]
  6. Kern E. R., Richards J. T., Overall J. C., Jr, Glasgow L. A. Alteration of mortality and pathogenesis of three experimental Herpesvirus hominis infections of mice with adenine arabinoside 5'-monophosphate, adenine arabinoside, and phosphonoacetic acid. Antimicrob Agents Chemother. 1978 Jan;13(1):53–60. doi: 10.1128/aac.13.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lauter C. B., Bailey E. J., Lerner A. M. Absence of idoxuridine and persistence of herpes simplex virus in brains of patients being treated for encephalitis. Proc Soc Exp Biol Med. 1975 Oct;150(1):23–27. doi: 10.3181/00379727-150-38966. [DOI] [PubMed] [Google Scholar]
  8. Lopez C., Watanabe K. A., Fox J. J. 2'-fluoro-5-iodo-aracytosine, a potent and selective anti-herpesvirus agent. Antimicrob Agents Chemother. 1980 May;17(5):803–806. doi: 10.1128/aac.17.5.803. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Mayo D. R. Differentiation of herpes simplex virus types 1 and 2 by sensitivity to (E)-5-(2-bromovinyl)-2'-deoxyuridine. J Clin Microbiol. 1982 Apr;15(4):733–736. doi: 10.1128/jcm.15.4.733-736.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Morahan P. S., Thomson T. A., Kohl S., Murray B. K. Immune responses to labial infection of BALB/c mice with herpes simplex virus type 1. Infect Immun. 1981 Apr;32(1):180–187. doi: 10.1128/iai.32.1.180-187.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Olson L. C., Buescher E. L., Artenstein M. S., Parkman P. D. Herpesvirus infections of the human central nervous system. N Engl J Med. 1967 Dec 14;277(24):1271–1277. doi: 10.1056/NEJM196712142772401. [DOI] [PubMed] [Google Scholar]
  12. Park N. H., Pavan-Langston D., McLean S. L., Albert D. M. Therapy of experimental herpes simplex encephalitis with aciclovir in mice. Antimicrob Agents Chemother. 1979 Jun;15(6):775–779. doi: 10.1128/aac.15.6.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schinazi R. F., Nahmias A. J. Different in vitro effects of dual combinations of anti-herpes simplex virus compounds. Am J Med. 1982 Jul 20;73(1A):40–48. doi: 10.1016/0002-9343(82)90061-4. [DOI] [PubMed] [Google Scholar]
  14. Schinazi R. F., Peters J., Williams C. C., Chance D., Nahmias A. J. Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice. Antimicrob Agents Chemother. 1982 Sep;22(3):499–507. doi: 10.1128/aac.22.3.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sloan B. J., Kielty J. K., Miller F. A. Effect of a novel adenosine deaminase inhibitor (co-vidarabine, co-V) upon the antiviral activity in vitro and in vivo of vidarabine (Vira-Atm) for DNA virus replication. Ann N Y Acad Sci. 1977 Mar 4;284:60–80. doi: 10.1111/j.1749-6632.1977.tb21937.x. [DOI] [PubMed] [Google Scholar]
  16. Sloan B. J., Miller F. A., Ehrlich J., McLean I. W., Machamer H. E. Antiviral activity of 0-beta-D-arabinofuranosyladenine. IV. Activity against intracerebral herpes simplex virus infections in mice. Antimicrob Agents Chemother (Bethesda) 1968;8:161–171. [PubMed] [Google Scholar]
  17. Watanabe K. A., Reichman U., Hirota K., Lopez C., Fox J. J. Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides. J Med Chem. 1979 Jan;22(1):21–24. doi: 10.1021/jm00187a005. [DOI] [PubMed] [Google Scholar]
  18. Whitley R., Lakeman A. D., Nahmias A., Roizman B. Dna restriction-enzyme analysis of herpes simplex virus isolates obtained from patients with encephalitis. N Engl J Med. 1982 Oct 21;307(17):1060–1062. doi: 10.1056/NEJM198210213071706. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES